3ZO Stock Overview
Acurx Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
+ 1 more risk
Acurx Pharmaceuticals, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$1.89 |
| 52 Week High | US$5.55 |
| 52 Week Low | US$1.21 |
| Beta | -1.9 |
| 1 Month Change | -13.21% |
| 3 Month Change | -42.32% |
| 1 Year Change | -28.87% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -60.97% |
Recent News & Updates
Recent updates
Shareholder Returns
| 3ZO | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 2.0% | 1.8% | 1.1% |
| 1Y | -28.9% | -23.5% | 1.9% |
Return vs Industry: 3ZO underperformed the German Biotechs industry which returned -24.4% over the past year.
Return vs Market: 3ZO underperformed the German Market which returned 2% over the past year.
Price Volatility
| 3ZO volatility | |
|---|---|
| 3ZO Average Weekly Movement | 11.3% |
| Biotechs Industry Average Movement | 5.0% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in DE Market | 10.2% |
| 10% least volatile stocks in DE Market | 2.5% |
Stable Share Price: 3ZO's share price has been volatile over the past 3 months.
Volatility Over Time: 3ZO's weekly volatility has decreased from 31% to 11% over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2017 | 4 | Dave Luci | www.acurxpharma.com |
Acurx Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections. The company’s lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that is in Phase 2b clinical trial to treat patients with clostridium difficile infections. It also develops ACX-375C, a potential oral and parenteral treatment targeting gram-positive bacteria, including methicillin-resistant staphylococcus aureus, vancomycin-resistant enterococcus, and penicillin-resistant streptococcus pneumonia.
Acurx Pharmaceuticals, Inc. Fundamentals Summary
| 3ZO fundamental statistics | |
|---|---|
| Market cap | €30.42m |
| Earnings (TTM) | -€13.60m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-2.4x
P/E RatioIs 3ZO overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 3ZO income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$14.58m |
| Earnings | -US$14.58m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
May 15, 2024
| Earnings per share (EPS) | -0.93 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did 3ZO perform over the long term?
See historical performance and comparison